RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unprecedented Review Fee Reduction
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/25/16 -- RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP)(FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced that …